Published Online
on September 23, 2002

A more recent version of this article appeared on November 1, 2002

This Article Full Text (PDF) All Versions of this Article: 40/5/763    most recent 01.HYP.0000036027.71527.3Ev1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schalcher, C. Articles by Kiowski, W. Search for Related Content PubMed PubMed Citation Articles by Schalcher, C. Articles by Kiowski, W. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB NITROGLYCERIN Related Collections Cardiovascular Pharmacology Other Vascular biology

Submitted on March 26, 2002
Revised on April 11, 2002

Interaction of Sildenafil With cAMP-Mediated Vasodilation In Vivo

Christoph Schalcher; Karin Schad; Hans Peter Brunner-La Rocca; Ruth Schindler; Erwin Oechslin; Christoph Scharf; Gabor Suetsch; Osmund Bertel; and Wolfgang Kiowski^*

From the Division of Cardiology, Department of Internal Medicine, University Hospital (C. Schalcher, K.S., H.P.B.-L., R.S., E.O., C. Scharf, G.S., W.K.), Zürich, Switzerland; and Triemli Hospital (O.B.), Zürich, Switzerland.

^* To whom correspondence should be addressed. E-mail: wolfgang.kiowski{at}hirslanden.ch.

Abstract—Sildenafil inhibits cGMP breakdown by phosphodiesterase 5. In vitro, increased cGMP levels inhibit cAMP breakdown by phosphodiesterase 3. It is uncertain, however, whether sildenafil increases biological effects of interventions increasing cAMP levels in vivo. The objective of the present study in 40 healthy male volunteers was to determine the existence and extent of interactions with sildenafil and vasodilators acting via cGMP or cAMP or independently from these mediators on the arterial tone of the human forearm. Forearm blood flow (FBF) responses (plethysmography) to brachial artery infusions of 3 doses each of nitroglycerin, which increases cGMP levels; of isoprenaline and milrinone, which increase cAMP levels; and of verapamil as a control were assessed at baseline and 80 minutes after 50 mg oral sildenafil in 10 volunteers each. Sildenafil increased FBF (2.5±0.1 to 3.5±0.2 mL/min per 100 mL, P<0.001; n=40). At equipotent vasodilator dosages, sildenafil increased FBF from 7.5±1.0 to 9.8±1.2 mL/min per 100 mL for nitroglycerin, from 8.3±1.0 to 10.4±1.4 mL/min per 100 mL for isoprenaline, and from 8.1±1.0 to 10.3±1.2 mL/min per 100 mL for milrinone and slightly decreased FBF from 7.7±1.3 to 7.1±1.2 mL/min per 100 mL for verapamil. ANOVA for repeated measures revealed a significant interaction between sildenafil and the type of vasodilator on FBF (P<0.01). The responses of FBF to nitroglycerin, milrinone, and isoprenaline after sildenafil were similarly increased compared with the response to verapamil (P<0.01). Sildenafil markedly enhanced the arterial vasodilator response to nitroglycerin, milrinone, and isoprenaline. The response to milrinone and isoprenaline is compatible with an interaction between cGMP and phosphodiesterase 3 or an enhancement of the NO component of cAMP-mediated vasodilation, and raises the possibility of enhanced biological effects of interventions leading to increases of cAMP in the presence of sildenafil.

Key words: cyclic GMP • cyclic AMP • muscle, smooth, vascular • human

This article has been cited by other articles:

				J. J. Oliver, V. P. Melville, and D. J. Webb Effect of Regular Phosphodiesterase Type 5 Inhibition in Hypertension Hypertension, October 1, 2006; 48(4): 622 - 627. [Abstract] [Full Text] [PDF]

				A. R. Hsu, K. E. Barnholt, N. K. Grundmann, J. H. Lin, S. W. McCallum, and A. L. Friedlander Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia J Appl Physiol, June 1, 2006; 100(6): 2031 - 2040. [Abstract] [Full Text] [PDF]

				B. A. Borlaug, V. Melenovsky, T. Marhin, P. Fitzgerald, and D. A. Kass Sildenafil Inhibits {beta}-Adrenergic-Stimulated Cardiac Contractility in Humans Circulation, October 25, 2005; 112(17): 2642 - 2649. [Abstract] [Full Text] [PDF]

				M. Komarek, A. Bernheim, R. Schindler, R. Steden, W. Kiowski, and H. P. B.-L. Rocca Vascular Effects of Natriuretic Peptides in Healthy Men Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2004; 9(4): 263 - 270. [Abstract] [PDF]

				S. Bahring, A. Rauch, O. Toka, C. Schroeder, C. Hesse, H. Siedler, G. Fesus, W. E. Haefeli, A. Busjahn, A. Aydin, et al. Autosomal-Dominant Hypertension With Type E Brachydactyly Is Caused by Rearrangement on the Short Arm of Chromosome 12 Hypertension, February 1, 2004; 43(2): 471 - 476. [Abstract] [Full Text] [PDF]

				T. Itoh, N. Nagaya, T. Fujii, T. Iwase, N. Nakanishi, K. Hamada, K. Kangawa, and H. Kimura A Combination of Oral Sildenafil and Beraprost Ameliorates Pulmonary Hypertension in Rats Am. J. Respir. Crit. Care Med., January 1, 2004; 169(1): 34 - 38. [Abstract] [Full Text] [PDF]

				D. H. Maurice Does Sildenafil Indirectly Inhibit Phosphodiesterase 3 in Vascular Smooth Muscle? Hypertension, March 1, 2003; e2(3): . [Full Text] [PDF]